Xenon Pharmaceuticals Inc.
NASDAQXenon Pharmaceuticals enters its June 2 earnings call in an unusual position: short sellers have been cutting exposure for a month, analysts keep raising targets, and yet the stock trades roughly 14% below the Street consensus — a gap that frames the setup heading into the next catalyst. Short interest has fallen sharply. At 5.2% of the free float, it now sits at its lowest level…
Snapshot as of 27 May 2026
Xenon Pharmaceuticals enters its June 2 earnings call in an unusual position: short sellers have been cutting exposure for a month, analysts keep raising targets, and yet the stock trades roughly 14% below the Street…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XENE — free to start on ORTEX.
Sign up for free →Open XENE on ORTEX